Role of intravenous naloxone in severe pruritus of acute cholestasis.
Pruritus is a well-known manifestation of various cholestatic disorders. Increased opioidergic tone is one of the mechanisms for this. This prospective, uncontrolled study was done to determine the efficacy of intravenous naloxone in pruritus of acute cholestasis. Twenty-two patients with severe pruritus (based on visual analogue scale [VAS] score of 0-100 and associated symptoms) were treated with intravenous naloxone (0.4 mg every 8 hours) for at least 48 hours. Viral hepatitis E was found to be the most common etiology for cholestatic pruritus (n=12). Eighteen patients (81.8%) patients had significant reduction in VAS after 48 hours of starting naloxone; these patients also showed reduction in alkaline phosphatase and gamma glutamyl transpeptidase. There was no side-effect or 'breakthrough' phenomenon noted in any patient over next 6 weeks. Naloxone is safe and efficacious in symptomatic improvement in cholestatic pruritus.
Joshi
Gunjan G
GG
Department of Gastroenterology, Choithram Hospital and Research Centre, Indore, 452 014, India.
Thakur
B S
BS
Sircar
Shohini
S
Namdeo
Arvind
A
Jain
Ajay K
AK
D000208:Acute Disease; D000328:Adult; D002779:Cholestasis / Q000150:complications*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D009270:Naloxone / Q000008:administration & dosage*; D011446:Prospective Studies; D011537:Pruritus / Q000188:drug therapy* / Q000209:etiology*
D009270:Naloxone